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ABSTRACT 
     The thesis entitled “Total synthesis of Pladienolide B and its 
analogues” has been alienated into FIVE chapters. Chapter I describes a 
brief introduction to (a) Natural product hybrids (b) Diverted Total 
Synthesis (DTS). Chapter II describes the total synthesis of pladienolide 
B. Chapter III describes the synthesis of truncated analogues of 
pladienolide B. Chapter IV describes the stereoselective syntheses of 
spiroacetals attenols A and B. Chapter V describes the synthesis of 
neolignan honokiol analogues. 
CHAPTER I: 
This Chapter describes a brief introduction to (a) Natural Prodcuct 
Hybrids; (b) Diverted Total Synthesis (DTS). 
CHAPTER II: 
This Chapter describes the “Total synthesis of pladienolide B”. 
     Pladienolides are 12-membered macrocyclic polyketides isolated from 
Streptomyces platensis Mer-11107 by way of an assay targeting that 
inhibit cell signalling pathways in a tumor-specific microenvironment. 
These novel polyketides contain a 12-membered macrocyclic core, a 12-
carbon diene side-chain, up to 11 stereocenters and an E-olefin 
embedded in the macrocyclic ring (Figure 1.1). Six of the seven 
pladienolides were reported to inhibit hypoxia-induced gene expression of 
vascular endothelial growth factor (VEGF) in U251 human glioma cells. 
The most active pladienolides B (2),C (3) and D (4) had IC50-values in the 
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low nanomolar range. Pladienolides have a unique mode of mechanistic 
action involving binding to the splicing factor SF3b an essential 
component of the spliceosome. Notably pladienolides B and D also 
caused in vivo tumor regression in several human cancer xenograft 
models. It has recently been reported that a derivative of pladienolide B 
has entered human clinical trials for cancer. The absolute configuration 
of 2 and 3 were recently determined by NMR and synthetic studies. The 
stereochemistry of the other congeners is unknown.   
 
 
 
 
 
Figure 1.1: Structures of pladienolides A-G 
Present Work:   
     The challenging architecture, in conjunction with the novel biological 
profile of pladienolide B prompted the total synthesis. From the 
retrosynthetic perspective (Scheme 1.1) Stille coupling was employed to 
append the side-chain 3 to the macrocyclic core 4, offering the E,E-diene 
system. The macrocyclic core 4 was synthesized by sequential 
esterification followed by ring closing metathesis (RCM) of hydroxy vinyl 
iodide (HVI) 6 and acid 7. The HVI 6 could be constructed by coupling 
vinyl iodo aldehyde 9 and Evan's amide 10, whereas the acid 8 realized 
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from commercially available geraniol. The side-chain moiety 3 was 
planned from the known epoxy alcohol 8 through the intermediate 5.  
 
 
 
 
 
 
 
 
 
 
Scheme 1.1: Retrosynthetic analysis of pladienolide B, 2. 
Synthesis of acid (7):  
     Geraniol was successively subjected to Sharpless asymmetric 
epoxidation followed by benzylation of alcohol with BnBr, NaH in THF 
afforded 11 in 79% yield. Opening of epoxide functionality using 
perchloric acid to furnish diol and the resultant diol was protected as an 
acetonide (2,2-DMP, cat. CSA in CH2Cl2) to provide 12 in 78% yield. 
Ozonolysis of trisubstituted olefin in 12 produced aldehyde, which on 
two carbon homologation using Ph3P=CHCOOEt offered α, β-unsaturated 
ester 13. Reduction of ester functionality in 13 with DIBAL-H followed by 
asymmetric epoxidation using Sharpless conditions afforded epoxy 
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alcohol 14 in 64% yield. Reductive opening of epoxy alcohol 14 to 1,3-
diol 15 was achieved with Red-Al in THF at −40 oC in 84% yield. 
Disilylation of 1,3-diol 15, followed by debenzylation with Raney-Ni 
furnished primary alcohol 16 in 84% yield. One carbon homologation of 
16 to 17 was obtained in two steps (oxidation followed by Wittig 
olefination). The selective cleavage of primary silyl ether in 17 followed by 
oxidation with BAIB/TEMPO provided acid 7 in 77% yield (Scheme 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.2:  
Synthesis of hydroxy vinyl iodide (HVI, 6):  
     Synthesis of 6 was started with nBu2BOTf mediated syn-aldol 
condensation of aldehyde 9 with oxazolidinone amide 10 to afford the 
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adduct 18 in 72% yield with good diastereoselectivity (>25:1). Silylation 
of 18 followed by reduction of chiral auxiliary with LiBH4 to yield primary 
alcohol 19 in 68% yield. Deoxygenation of alcohol in 19 was 
accomplished in two steps via tosylation and LiAlH4 reduction to attain 
20 in 80% yield. TBAF mediated desilylation of 20 gave HVI 6 in 96% 
yield (Scheme 1.3).  
      
 
 
 
 
 
Scheme 1.3 
Synthesis of macrocyclic core (4): 
     The construction of the macrolactone core 4 achieved as shown in 
Scheme 1.4. Esterification of acid 7 with HVI 6 was realized under 
Yamaguchi conditions to furnish fully functionalized ester 21 in 74% 
yield. Hydrolysis of isopropylidine group and TBS ether using 
PPTS/MeOH offered corresponding triol 22 in 88% yield. Triol 22 
underwent RCM with HG-II catalyst in the presence of 1,4-benzoquinone 
provided macrolactone which was subjected to regioselective acetylation 
with Ac2O in py at –10 oC was very efficient to furnish acetate 4 in 47% 
yield. 
N
O
OO
Bn
OH
I
OTBS
I OH
OTBS
I
19
10, nBu2BOTf
Et3N, CH2Cl2,
–78 oC, 6 h, 72%
i. TBSOTf, DIPEA,
CH2Cl2, –78
oC, 2 h,
92%
ii. LiBH4, EtOH, THF,
0 oC-rt, 8 h, 74%
i. Ts2O, Et3N,
CH2Cl2, –10
oC, 1 h
ii. LiAlH4, Et2O, –30
oC,
12 h, 80% (2 steps)
N
O
OO
Bn
10 18
20
TBAF, THF
rt, 2 h, 96%
OH
I
6
XVIII 
 
 
 
 
Scheme 1.4:  
Synthesis of side-chain moiety (3):  
     The side-chain 3 was synthesized starting from known epoxy alcohol 
8 as shown in Scheme 1.5. TBSOTf mediated intramolecular hydride 
transfer in epoxy alcohol 8 gave silyloxy aldehyde 23 (78%). The 
vinylmagnesium bromide addition onto aldehyde 23 followed by MnO2 
oxidation afforded enone 24 in 81% yield. Enantioselective reduction of 
enone 24 with (S)-CBS reagent and BH3.SMe2 gave allylic alcohol 25 
(82%, dr = 95:5). Propionylation ((C2H5CO)2O, Et3N in CH2Cl2) of alcohol 
25 furnished ester 5 (95%) and subsequent Ireland–Claisen 
rearrangement with LDA and TBSCl in the presence of HMPA gave acid 
26 with additional asymmetric carbon at C16 position. Reduction of acid 
functionality in 26 with LiAlH4 provided primary alcohol 27 (75%). The 
Corey protocol was employed to synthesize the alkyne 29 via dibromide 
28 in 82% yield. Desilylation of 29 using TBAF afforded the homoallylic 
alcohol 30 which was exposed to Shi epoxidation conditions produced 
epoxy alkyne 3. 
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Scheme 1.5:  
Synthesis of Pladienolide B (2):  
     With access to the side-chain 3 and macrolide 4, we sought to couple 
these employing the Stille coupling. In the event, exposing the side chain 
fragment 3 to nBu3SnH in the presence of Pd(PPh3)4 to afford unstable 
vinylstannane, which was immediately coupled with macrolactone 4 in 
the presence of Pd-catalyst, Ph3As, LiCl in NMP afforded the desired 
pladienolide B (2) in 68% yield (Scheme 1.6).  
 
 
Scheme 1.6:  
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     In conclusion, a convergent synthetic route has been achieved 
efficiently. The synthetic highlights include Sharpless asymmetric 
epoxidation, Ireland-Claisen rearrangement, ring closing metathesis, Shi 
epoxidation and Stille coupling. 
CHAPTER III: 
This Chapter describes the “Synthesis of truncated analogues of 
pladienolide B”. 
     Pladienolides A-G were isolated from streptomyces platensis Mer-
11107 by way cell based assay that inhibit cell signaling pathways. Six of 
the seven pladienolides were reported to inhibit hypoxia-induced gene 
expression of VEGF in human glioma cells. Interestingly, pladienolides B, 
C and D all have the C7 acetyl group and showed good biological activity. 
Lack of this acetate decreased activity by more than two orders of 
magnitude as witnessed by pladienolides A, F and G (Table 1.1). 
Pladienolides B and D also caused in vivo tumor regression in several 
human xenograft models.  
Table 1.1: 
Compound 
Anti-VEGF-PLAP 
activity 
IC50 (nM) 
Anti-proliferative 
activity 
IC50 (nM) 
Pladienolide B (2) 1.8 3.5 
Pladienolide D (4) 5.1 6.0 
Pladienolide C (3) 7.4 14.7 
Pladienolide E (5) 65.2 146.8 
Pladienolide A (1) 451.5 967.5 
Pladienolide F (6) 2894.2 2595.2 
Pladienolide G (7) > 10000.0 > 10000.0 
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      Our interest in pladienolide B and closely related congeners was 
prompted by the highly interesting biological profile displayed by this 
family of natural products. The highly potent in vitro and in vivo 
antitumor activity as well as the unique mechanism of action presented 
by this class of compounds makes pladienolide B a promising lead 
structure in the identification of novel anti-tumor agents. As part of our 
programme to design and synthesis of novel anti-cancer agents based on 
natural products, we selected new pladienolide B analogues as our target 
molecules. The truncated analogues of pladienolide B were designed with 
aromatic substituents in place of side-chain to know the side-chain 
importance in biological activity (Figure 1.2).   
 
 
 
 
 
Figure 1.2: 
Present Work: 
     From retrosynthetic analysis (Scheme 1.7) truncated analogues (31a-
d) could be synthesized from alcohols 32a-d and acid 7 by employing 
sequential Yamaguchi esterification and RCM reactions. Alcohols 32a-d 
could be obtained from MgCl2 catalyzed anti-aldol reaction between 
aromatic aldehydes 33a-d and oxazolidinone 34 with ease. 
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Scheme 1.7: Retrosynthetic analysis of pladienolide B analogues 
Synthesis of truncated analogues of pladienolide B (31a-d): 
     The syntheses commenced with MgCl2 anti-aldol reaction between 
oxazolidinone 34 and aromatic aldehydes 33a-d to afford adducts 35a-d 
in 84-94% yield. These adducts were silylated as TBS-ethers 36a-d and 
removal of chiral auxiliary with LiBH4 provided primary alcohols 37a-d. 
One carbon homologation of 37a-d accomplished in two steps (oxidation 
and methylenation) gave olefins 38a-d in 60-69% yield. TBAF mediated 
desilylation of 38a-d provided homoallylic alcohols 39a-d in 86-96% 
yield.  Esterification of alcohols 39a-d with previously synthesized acid 7 
under Yamaguchi conditions afforded esters 40a-d and under acid 
hydrolysis conditions provided triols 41a-d. The central 12-membered 
lactones 42a-d were formed in moderate yields through RCM using 
Hoveyda-Grubbs 2nd generation catalyst in the presence of 1,4-
benzoquinone at reflux temperature from triols 41a-d. Finally, 
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regioselective acetylation of more nucleophilic hydroxy group (C7) gave 
the desired truncated analogues of pladienolide B 43a-d in 86-94% yield 
(Scheme 1.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.8:  
     In summary, syntheses of four truncated analogues of pladienolide B 
were achieved using MgCl2 anti-aldol reaction, Yamaguchi esterification 
and RCM as key reactions. The biological evaluation of synthetic 
pladienolide B and designed truncated analogues were performed against 
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three cancer cell lines and showed that, the designed analogues inhibits 
tumor moderately.  
CHAPTER IV: 
This Chapter describes the “Stereoselective syntheses of 
spiroacetals attenols A and B”. 
     Two novel isomeric etheral compounds by Uemura et al. from the 
dichloromethane-soluble fraction of the ethanol extract of the Chinese 
biovalve Pinna attenuata and named as attenol A (43) and attenol B (44, 
Figure 1.3). These bicyclic triols exhibit moderate cytotoxicity against 
P388 cells at IC50 24 and 12 µg/mL, respectively. Attenols possess same 
molecular formulae but differ in the two hydroxy groups which 
participate in the spiroketal linkage. Attenol A comprises a [5,4] 
spiroketal unit and attenol B featuring a dioxa-bicyclo [3.2.1]octane unit. 
Attenol A features a spiroketal ring embedded with six stereocentres, a 
disubstituted (Z)-olefin and terminal olefin.  
 
 
 
 
 
Figure 1.3: 
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Present Work: 
     As shown in Scheme 1.9 attenols A and B were constructed from 
ketone 45 in one step by acid catalyzed spiroketalization. The advanced 
ketone 45 could be constructed from alkynone 46, which in turn may be 
built from the alkyne 47 and the aldehyde 48. The fragments 47 and 48 
could be obtained from known aldehyde 49 and amide 50, respectively.  
 
 
 
 
 
 
 
 
 
 
Scheme 1.9: Retrosynthetic analysis of attenols A and B 
Synthesis of alkyne 47:  
     Synthesis of terminal alkyne 47 commenced from the known 
aldehyde 49 in 11 steps as illustrated in Scheme 1.10. Treatment of 
aldehyde 49 with lithiated ethyl propiolate afforded the propargylic 
alcohol 51. Exposure of γ-hydroxy ynoate 51 to the Lu protocol 
(PPh3/benzene) provided dienoate 52 with 97% diastereocontrol of the  
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Scheme 1.10 
E,E-isomer. Using Sharpless dihydroxylation conditions [(DHQ)2PHAL, 
K3Fe(CN)6, K2CO3, OsO4 and MeSO2NH2], dienoate 52 proceeded to the 
diol 53 and the resultant diol was treated with triphosgene, Et3N in 
CH2Cl2 to attain carbonate 54 (94%). Pd2(dba)3·CHCl3/Ph3P catalyzed 
reduction of 54 at allylic position using mild hydride source 
(Et3N/HCOOH) in THF offered δ-hydroxy enoate 55 (89%). Silylation of 
secondary alcohol to 56 followed by ester reduction with DIBAL-H offered 
allylic alcohol 57 in 84% yield. Stereoselective epoxidation of allylic 
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alcohol 57 with mCPBA afforded a mixture of the anti- and syn-epoxides 
in 20:1 ratio, from which anti- epoxide 58 could be isolated by column 
chromatography in 83% yield. Epoxy alcohol 58 was converted to 
corresponding chloride and treated with lithium diisopropylamide (LDA) 
in THF provided alkynol 59. Desilylation of TBS-ether and protection of 
1,3-diol as an acetonide 47 using 2,2-DMP and cat. CSA in CH2Cl2 in 
97% yield. 
Synthesis of aldehyde 36: 
 
 
 
 
 
 
 
 
Scheme 1.11:  
     Hydroboration [9-BBN, pH 7 buffer, 30% H2O2] of terminal double 
bond in 50 offered alcohol, which was immediately silylated as a TBS-
ether 61 in 72% yield. Reductive cleavage of chiral auxiliary was achieved 
with LiBH4 provided alcohol 62. Oxidation of alcohol to aldehyde 63 and 
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subsequent Julia–Kocienski olefination with sulfone 64 in presence of 
KHMDS afforded E-olefin 65 as a single isomer (78%). Sharpless 
conditions (AD-mix-β and CH3SO2NH2) employed to 65 to install vicinal 
diol (66) and diol protected as an acetonide (2,2-DMP, cat. CSA in 
CH2Cl2) afforded fully and differentially protected compound 67 (96%). 
Selective TBS cleavage under mild acidic conditions [PPTS/ethanol] 
offered the primary alcohol 68 and Swern oxidation of alcohol led to the 
construction of the aldehyde segment 48 in 84% yield (Scheme 1.11). 
Synthesis attenols A and B:  
     With 47 and 48 in hand, the stage was set to couple these fragments. 
Coupling of lithiated alkyne (generated from alkyne 47 and nBuLi in 
THF) and aldehyde 48 ended with diastereomeric alkynol, which on 
MnO2 oxidation offered alkynone 46 (75% yield). One-pot reduction of 
alkyne functionality and PMB-ether deprotection using Pd/C under H2 
atmosphere afforded primary alcohol 69 in 92% yield. One carbon 
homologation of 69 via oxidation and Wittig reaction furnished olefin 70 
in 74% yield. Desilylation of 70 with TBAF produced primary alcohol 71 
in 95% yield. DMP oxidation of alcohol to aldehyde and subsequent cis-
Wittig reaction with phosphonium salt 72 and KHMDS in THF at −30 oC 
offered acyclic ketone 45 with (Z)-olefin in 89% yield. Finally, one-pot 
global deprotection followed by spiroketalization was achieved with p-TSA 
in methanol to provide the desired spiroketal isomers attenols A and B in 
52% and 12% yields, respectively (Scheme 1.12). 
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Scheme 1.12 
     In summary, stereoselective total syntheses of attenols A and B have 
been achieved using Sharpless asymmetric dihydroxylation, Pd(0)-
catalyzed allylic reduction, stereoselective mCPBA epoxidation and Julia-
Kocienski olefination reactions as key steps. 
CHAPTER V: 
This Chapter describes the “Synthesis of neolignan honokiol 
analogues”. 
 The root and stem bark of the oriental herb Magnolia officinalis (also 
known as Houpo) or Magnoliae obovata have been used in traditional 
Chinese and Japanese medicines for treatment of various diseases like 
flu, anxiety and allergy. Early research on these traditional medicines 
has identified honokiol 73 and its structural isomer magnolol 74 as 
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active compounds (Figure 1.4). The structure of 73 consists of a biphenyl 
skeleton with ortho, para-C,C- coupling of para-allyl and ortho-allyl 
phenols. Honokiol has demonstrated neurotrophic activity at 0.1 to 1 µM 
concentrations on the cultures of rat cortical neurons. 
 
 
 
Figure 1.4: 
     A SAR study has been already performed on a few compounds where 
double bonds were reduced and phenols selectively protected. The 
results revealed that the 4′-phenol and 5-allyl group are essential for 
neurotrophic activity. As part of our CNS program on the development of 
novel neurotrophic agents based on natural products new analogues of 
honokiol as target molecules. We designed honokiol analogues with 
various substituents at 5′-allyl position. Further, we studied the effect of 
the substitution of two phenol groups by preparing corresponding methyl 
ethers (Figure 1.5).  
 
 
 
Figure 1.5: 
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Present Work: 
     As shown in Scheme 1.13 a convergent and versatile synthetic route 
to produce designed analogues of 73, i.e., compounds from Series I, II 
and III depending upon the number of free phenol groups. Pd-catalyzed 
Suzuki-Miyaura coupling could be employed to construct biaryls (75a-h, 
76a-h, 77a-h) from bromides (78a-h, 79a-h) and boronate 82. The 
aromatic bromides with various heterocyclic and carbonyl groups at α-
position to O-methyl/hydroxyl group could be easily obtained from 
propargyl ketone 80, which could be synthesized  from 5-
bromosalicylaldehyde 81. 
 
   
 
 
 
 
 
 
Scheme 1.13: Retrosynthetic analysis  
Synthesis of ketone 80: 
     The synthesis of ketone 80 starts with O-methylation of 5-bromo 
salicylaldehyde 81 followed by ethynylmagnesium bromide addition gave 
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propargylic alcohol 82. Jones oxidation of alcohol 82 gave the ketone 80 
in 78% yield (Scheme 1.14). 
 
 
 
Scheme 1.14:  
Syntheses of 83a-f and 84a-f: 
 
 
 
 
 
 
 
 
 
 
Scheme1.15: Regents and conditions: a) R1C=NH(NH2).HCl, Na2CO3, 
CH3CN, reflux, 8 h; b) RNHNH2, 4 Å MS, EtOH, reflux, 12 h; c) 
ethylacetoacetate, ammonium acetate, ZnBr2, toluene, reflux, 24 h; d) 
2,3-dimethyl-1,3-butadiene, PhMe, 80 oC, 24 h; e) benzylazide, EtOH, 
reflux, 24 h; f) BCl3.DMS (2M in CH2Cl2), dichloroethane, 24 h. 
     Key intermediate 80 in hand, stage was set for the preparation of the 
required intermediates. Ketone 80 was refluxed with amidine 
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hydrochlorides and Na2CO3 provided corresponding pyrimidines 83a-c. 
Pyrazoles 83d,e were prepared in excellent yields by refluxing 8 with 
hydrazines in ethanol for 12 h. The pyridine derivative 83f was obtained 
by treating 80 using Bohlmann-Rahtz conditions. Treatment of ketone 
80 with 2,3-dimethyl-1,4-butadiene in toluene provided Diels-Alder 
adduct 83f in 87% yield. Ketone 80 exposed to benzyl azide in ethanol 
afforded triazole 83h (94%). The second series of intermediates 84a-h 
were synthesized from demethylation of 83a-h using BCl3.Me2S in 
CH2Cl2 (Scheme 1.15). 
Series I analogues: 
     The series I analogues (75a-h) have both phenol functions protected 
as methyl ethers. The Pd(PPh3)4 catalyzed Suzuki-Miyaura coupling 
between aryl bromides 83a-h and boronic acid 85 and Na2CO3 at reflux 
temperature afforded series I analogues (75a-h) in 76-92% yield (Scheme 
1.16).  
 
 
 
 
 
*  Numbers mentioned in the brackets are respective isolated yields. 
Scheme 1.16:  
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Series II and III analogues: 
     The series II derivatives (77a-h) were obtained by Pd(PPh3)4 catalyzed 
Suzuki-Miyaura cross coupling reaction between aryl bromides 84a-h 
and aryl boronic acid 85. Demethylation of 77a-h using BCl3.Me2S 
offered series III compounds (76a-h) in 48-95% yield (Scheme 1.17 and 
Table 1.2). 
 
 
 
 
 
 
 
*  Numbers mentioned in the brackets are respective isolated yields. 
Scheme 1.17: 
     In conclusion, an efficient synthetic route affording the analogues of 
neolignan has been developed. The new analogues were tested against 
neuro2A cell lines and found that they promote neurite growth 
moderately. 
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